HIV treatment, now commonly known as Antiretroviral therapy (ART) has been in use since the first drug Zidovine (AZT) was discovered in 1987. Subsequent developments have aimed at maximising the benefits of the treatment while also minimising side effects and increasing tolerability through simplification.
The CARES study, the first of its kind in Africa sets out to determine if the use of Long-acting injectable ART is feasible, safe and efficacious in a public health set up in Africa. With funding from Janssen EMEA and drug donations from both manufactures of Cabotegravir ((Viiv/GSK) and Rilpivirine (Janssen), a multi national clinical trial, coordinated by the Joint C clinical Research Centre has been set up. The overall aim of this study is to determine/demonstrate that switching from taking daily ART pills to injectable long acting RPV +CAB will not reduce the effectiveness of the ART on the participants.
A target of 512 participants, will be enrolled in this study and randomized 1:1 to either continue on their ART or switch to the intervention for a treatment period of 24 months. Eligible participants must meet the following criteria:
Joint Clinical Research Centre- Lubowa (JCRC) situated on Entebbe Road on the outskirts of Kampala City in Uganda is a well-equipped research organization that pioneered the fight against HIV in Uganda since 1991.